Mid-cap biotech Telix Pharmaceuticals Ltd (ASX:TLX)’s shares are on a tear, up 6% to $9.68, after the company posted a sharp lift in full-year revenue and issued upbeat growth guidance.
Revenue for FY25 jumped 56% to $US803.8 million, meeting its upgraded full-year guidance.
For FY26, Telix is guiding to revenue of $US950 million to $US970 million, including product sales in jurisdictions where it holds marketing authorisation and a full-year contribution from the RLS Radiopharmacies (RLS) acquisition. R&D spending is expected to be $US200 million to $US240 million.
Chief executive Dr Christian Behrenbruch said the outlook “reflects our confidence in sustaining the momentum of our core cash generative business”. He said the group was reinvesting earnings to “prioritize the acceleration of our best-in-class therapeutic pipeline”, which now includes 3 pivotal-stage trials in prostate, kidney and brain cancer.
Telix reported a non-material loss before tax of $US5.3 million.